Mycophenolate mofetil for treatment of refractory lupus nephritis: four pilot cases

Wallman, Lucinda; Stewart, Graham; Chapman, Joab; O’Connell, Philip; Fulcher, David A.

doi:10.1111/j.1445-5994.2000.tb04366.x

Cited by 11 publications

(8 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While ethnicity plays a role in the response to immunosuppressive treatment in LN [34], it seems that the response to MF in refractory or relapsing disease does not differ in patients from different ethnic groups. In fact, the cases reported to date are from the USA [8,18,19], South America [13,26], Canada (in children) [35], Europe [9,10,12,14,20,23,24,25,30], Australia [21], and Asia [11,22,27,28,29]. …”

Section: Discussionmentioning

confidence: 99%

“…Subsequently, several observational and uncontrolled studies also described the beneficial effect of MF in refractory or relapsing LN, indicating that switching from CYC to MF is a reasonable alternative strategy [9,10,11,12,13,14,21,22,23,24,25,26,27,28,29]. Since the dose of prednisone in our study was low and decreased during follow-up, administration of MF could obviate the need for corticosteroids [8,9,18,30].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Mycophenolate in Refractory and Relapsing Lupus Nephritis

Rivera

Mérida²,

Illescas³

et al. 2014

Am J Nephrol

View full text Add to dashboard Cite

Background: Mycophenolate (MF) is effective as induction and maintenance treatment in patients with lupus nephritis (LN). This study evaluates the efficacy and safety of MF in patients with refractory and relapsing LN. Methods: Data were retrospectively obtained for 85 patients (35 refractory and 50 relapsing) from 11 nephrology departments in Spain. The primary endpoints were the incidence and cumulative number of renal responses and relapses and their relationship with baseline clinical and analytical data. The secondary endpoint was the appearance of side effects. Results: The main clinical and analytical variables were similar both in refractory and relapsing LN. Most of the patients had received cyclophosphamide, and all of them switched to MF. 74 patients (87%) achieved a response (69% partial, 31% complete). Age at starting MF, gender, pathological classification, body mass index, blood pressure, baseline renal function, and proteinuria were not associated with achieving response. After stopping MF, 3 of 19 patients (15.7%) relapsed, all at 6 months of follow-up. No differences were found between clinical and analytical variables and number of relapses. Side effects were unremarkable, except for 1 patient, who died of thrombocytopenia and ovarian hemorrhage. Conclusions: Switching to MF from other immunosuppressive treatments is effective and safe in refractory and relapsing LN.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Mycophenolate in Refractory and Relapsing Lupus Nephritis

Rivera

Mérida²,

Illescas³

et al. 2014

Am J Nephrol

View full text Add to dashboard Cite

show abstract

“…Успешное применение ММФ у больных с высо-ким риском развития БТПХ предполагало подавление про-цессов избыточного фиброзообразования. Интересно, что при лечении ММФ люпус-нефрита отмечено уменьшение выраженности гломерулосклероза и интерстициального фиброза [16]. Эти данные позволили предположить, что ММФ влияет на функции фибробластов, связанные с зажи-влением и образованием рубцовой ткани.…”

Section: гу институт ревматологии рамн москваunclassified

Prospects for using mycophenolate mofetil in diffuse scleroderma

Ананьева¹

2009

Modern Rheumatology Journal

View full text Add to dashboard Cite

“…Damit war die MMF-Therapie der CYC-BoliTherapie in den untersuchten Endpunkten überlegen, Daten zum Langzeitverlauf und zu klinischen Endpunkten wie Rezidivrate und Rate langfristig terminal Niereninsuffizienter fehlen auch in dieser Studie. Es gibt noch weitere Einzelberichte über die gute Wirksamkeit von MMF vor allem bei den Patienten, die unter CYC-Therapie einen refraktären Verlauf zeigten [33][34][35] …”

Section: Euro-protokollunclassified

Rheumatologie—Teil 2

Ahmadi‐Simab

Hellmich²,

Lamprecht³

et al. 2006

Med Klin

View full text Add to dashboard Cite

Due to the partial elucidation of the immunopathogenesis of chronic inflammatory diseases during the last years, clinical rheumatology has made a rapid development, which by the consequent use of immunomodulatory therapies including recombinant proteins (biologicals) led to a significantly ameliorated prognosis of these diseases. On this basis, new research projects are continuously performed in the fields of pathogenesis, new drug development, outcome and therapy studies. New developments of imaging techniques and serologic testing facilitate a better classification and definition of disease activity and remission criteria. The current state of research in the field of collagen vascular diseases with its clinical consequences is reviewed in this article on the basis of the most recent data available.

show abstract

Mycophenolate mofetil for treatment of refractory lupus nephritis: four pilot cases

Abstract: Cuse 2: A 33-year-old Thai female had a long history of SIB dating back to the age of ten years, manifest by arthritis, skin rash, focal proliferative lupus nephritis, cutaneous vasculitis, recurrent thrombocytopenia, Aust NZ J Med 2000; 30 WALLMAN ET AL.

Cited by 11 publications

References 26 publications

Mycophenolate in Refractory and Relapsing Lupus Nephritis

Mycophenolate in Refractory and Relapsing Lupus Nephritis

Prospects for using mycophenolate mofetil in diffuse scleroderma

Rheumatologie—Teil 2

Contact Info

Product

Resources

About